MCID: AVN001
MIFTS: 56

Avian Influenza

Categories: Infectious diseases, Oral diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Avian Influenza

MalaCards integrated aliases for Avian Influenza:

Name: Avian Influenza 12 58 3 15 17
Influenza in Birds 43 71
Bird Flu 12 42
Avian Flu 12

Characteristics:

Orphanet epidemiological data:

58
avian influenza
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare respiratory diseases
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:4492
MeSH 43 D005585
SNOMED-CT 67 55604004
ICD10 32 J09.X
ICD10 via Orphanet 33 J09
Orphanet 58 ORPHA454836
UMLS 71 C0016627

Summaries for Avian Influenza

MedlinePlus : 42 Birds, just like people, get the flu. Bird flu viruses infect birds, including chickens, other poultry, and wild birds such as ducks. Usually bird flu viruses only infect other birds. It is rare for people to get infected with bird flu viruses, but it can happen. Two types, H5N1 and H7N9, have infected some people during outbreaks in Asia, Africa, the Pacific, the Middle East, and parts of Europe. There have also been some rare cases of other types of bird flu affecting people in the United States. Most of the people who get bird flu have had close contact with infected birds or with surfaces that have been contaminated by the birds' saliva, mucous, or droppings. It is also possible to get it by breathing in droplets or dust that contain the virus. Rarely, the virus has spread from one person to another. It may also be possible to catch bird flu by eating poultry or eggs that are not well cooked. Bird flu illness in people can range from mild to severe. Often, the symptoms are similar to the seasonal flu, such as Fever Cough Sore throat Runny or stuffy nose Muscle or body aches Fatigue Headaches Eye redness (or conjunctivitis) Difficulty breathing In some cases, bird flu can cause serious complications and death. As with seasonal flu, some people are at higher risk for serious illness. They include pregnant women, people with weakened immune systems, and adults 65 and older. Treatment with antiviral medicines may make the illness less severe. They may also help prevent the flu in people who were exposed to it. There is currently no vaccine available to the public. The government does have a supply of a vaccine for one type of H5N1 bird flu virus and could distribute it if there was an outbreak that spread easily from person to person. Centers for Disease Control and Prevention

MalaCards based summary : Avian Influenza, also known as influenza in birds, is related to conjunctivitis and newcastle disease, and has symptoms including fever, pruritus and snoring. An important gene associated with Avian Influenza is FURIN (Furin, Paired Basic Amino Acid Cleaving Enzyme), and among its related pathways/superpathways are Innate Immune System and PAK Pathway. The drugs Oseltamivir and Probenecid have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and t cells, and related phenotypes are cardiovascular system and hematopoietic system

Disease Ontology : 12 An influenza that results in infection located in respiratory tract of humans, domestic and wild birds, has material basis in Influenza A virus, which is transmitted by contact with infected poultry. Five strains of avian influenza A viruses (H5N1, H7N3, H7N2, H7N7 and H9N2) are known to cause human infections. The infection has symptom fever, has symptom cough, has symptom sore throat, has symptom muscle aches, has symptom nausea, has symptom diarrhea, has symptom vomiting, has symptom neurologic changes, has symptom pneumonia, and has symptom acute respiratory distress.

CDC : 3 Avian influenza refers to the disease caused by infection with avian (bird) influenza (flu) Type A viruses. These viruses occur naturally among wild aquatic birds worldwide and can infect domestic poultry and other bird and animal species. Avian flu viruses do not normally infect humans. However, sporadic human infections with avian flu viruses have occurred. The links below offer more information about avian influenza.

Wikipedia : 74 Avian influenza-known informally as avian flu or bird flu is a variety of influenza caused by viruses... more...

Related Diseases for Avian Influenza

Diseases related to Avian Influenza via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 363)
# Related Disease Score Top Affiliating Genes
1 conjunctivitis 31.9 TNF IL6 CXCL8
2 newcastle disease 31.6 TNF NEU1 IVNS1ABP IRF7 IFNA1 DDX58
3 bronchitis 31.6 TNF IL6 CXCL8 CXCL10
4 plague 31.6 TNF IL6 DDX58 CCR5
5 swine influenza 31.6 TNF NEU1 IFNA1 DDX58
6 influenza 31.5 TNF NEU1 IVNS1ABP ISG15 IRF7 IL6
7 encephalitis 31.2 TNF IL6 DDX58 CXCL10 CCR5
8 respiratory failure 31.1 TNF SFTPD JUN IL6 CXCL8 CXCL10
9 bacterial infectious disease 31.1 TNF ISG15 IL6 CXCL8
10 cholera 31.0 TNF NEU1 IL6 CXCL8
11 diarrhea 31.0 TNF IL6 IFNA1 CXCL8
12 viral pneumonia 31.0 TNF SFTPD IL6 DDX58 CXCL8 CXCL10
13 pneumonia 31.0 TNF SFTPD NEU1 IL6 CXCL8 CXCL10
14 stomatitis 31.0 TNF IL6 IFNA1 DDX58 CXCL8
15 west nile virus 30.9 IFNA1 DDX58 CCR5
16 severe acute respiratory syndrome 30.9 TNF IL6 IFNA1 FURIN DDX58 CXCL8
17 bronchopneumonia 30.8 TNF IL6 CXCL8
18 bacterial pneumonia 30.8 TNF SFTPD NEU1 IL6 CXCL8
19 bronchiolitis 30.7 TNF SFTPD IL6 CXCL8 CXCL10
20 gastroenteritis 30.7 TNF IL6 IFNA1 CXCL8
21 salmonellosis 30.7 TNF JUN IL6
22 vaccinia 30.7 TNF STAT2 ISG15 IRF7 IL6 IFNA1
23 streptococcal toxic-shock syndrome 30.6 TNF IL6 CXCL8
24 japanese encephalitis 30.6 TNF IVNS1ABP CXCL10
25 chlamydia 30.6 TNF IL6 CXCL8
26 adult respiratory distress syndrome 30.6 TNF SFTPD IL6 CXCL8
27 thrombocytopenia 30.6 TNF IL6 IFNA1 CXCL8 CXCL10
28 cryptogenic organizing pneumonia 30.6 TNF SFTPD CXCL8
29 leptospirosis 30.6 TNF IL6 CXCL8
30 hepatitis e 30.5 TNF ISG15 DDX58
31 exanthem 30.5 TNF IL6 CXCL8
32 rabies 30.5 STAT2 IRF7 IFNA1 DDX58 CXCL10
33 respiratory allergy 30.5 TNF IL6 CXCL8
34 pericarditis 30.5 TNF IL6 CXCL8
35 keratitis, hereditary 30.5 TNF IL6 CXCL8
36 toxic shock syndrome 30.5 TNF IL6 CXCL8
37 tick-borne encephalitis 30.5 IVNS1ABP DDX58 CXCL10 CCR5
38 lung disease 30.5 TNF SFTPD IL6 CXCL8 CXCL10 CCR5
39 chikungunya 30.4 TNF IL6 HSP90AA1 FURIN DDX58
40 bronchiolitis obliterans 30.4 TNF SFTPD IL6 CXCL8
41 pertussis 30.4 TNF JUN IL6 CXCL8
42 lyme disease 30.3 TNF IRF7 IL6 IFNA1
43 autoimmune disease 30.3 TNF IL6 IFNA1 CXCL8 CCR5
44 acquired immunodeficiency syndrome 30.3 TNF IL6 IFNA1 CCR5
45 measles 30.2 TNF STAT2 IRF7 IL6 IFNA1 DDX58
46 human immunodeficiency virus type 1 30.1 TNF IL6 IFNA1 CXCL10 CCR5
47 pulmonary disease, chronic obstructive 30.0 TNF SFTPD IL6 CXCL8 CXCL10 CCR5
48 kaposi sarcoma 29.9 JUN IRF7 IL6 IFNA1 CXCL8 CCR5
49 immune deficiency disease 29.8 TNF JUN IL6 IFNA1 FURIN CXCL10
50 colon adenocarcinoma 29.4 TNF JUN FURIN CXCL8

Graphical network of the top 20 diseases related to Avian Influenza:



Diseases related to Avian Influenza

Symptoms & Phenotypes for Avian Influenza

UMLS symptoms related to Avian Influenza:


fever, pruritus, snoring, coughing

MGI Mouse Phenotypes related to Avian Influenza:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.14 CCR5 CRK CXCL10 FURIN IL6 IVNS1ABP
2 hematopoietic system MP:0005397 10.1 CCR5 CXCL10 DDX58 FURIN IL6 IRF7
3 homeostasis/metabolism MP:0005376 10.07 CCR5 CRK CXCL10 DDX58 IL6 IRF7
4 immune system MP:0005387 10 CCR5 CXCL10 DDX58 FURIN HSP90AA1 IL6
5 digestive/alimentary MP:0005381 9.97 CCR5 CRK DDX58 FURIN IL6 PCSK5
6 mortality/aging MP:0010768 9.86 CCR5 CRK CXCL10 DDX58 FURIN HSP90AA1
7 respiratory system MP:0005388 9.28 CRK IL6 IVNS1ABP JUN NEU1 PCSK5

Drugs & Therapeutics for Avian Influenza

Drugs for Avian Influenza (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 42)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
2
Probenecid Approved, Investigational Phase 4 57-66-9 4911
3 Anti-Infective Agents Phase 4
4 Antiviral Agents Phase 4
5 Renal Agents Phase 4
6 Antirheumatic Agents Phase 4
7
Formaldehyde Approved, Vet_approved Phase 2, Phase 3 50-00-0 712
8
Lactitol Investigational Phase 3 585-88-6, 585-86-4 493591
9 Hemagglutinins Phase 3
10 Agglutinins Phase 3
11 Cathartics Phase 3
12 Immunosuppressive Agents Phase 3
13 Laxatives Phase 3
14
Tocopherol Approved, Investigational Phase 2 1406-66-2, 54-28-4 14986
15
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
16
Aluminum sulfate Approved Phase 2 10043-01-3
17
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2 59-02-9 14985
18 Tocotrienol Investigational Phase 2 6829-55-6
19 N-(2-aminoethyl)-5-isoquinolinesulfonamide Phase 2
20 MF59 oil emulsion Phase 2
21 Tocopherols Phase 2
22 Tocotrienols Phase 2
23 Pharmaceutical Solutions Phase 1, Phase 2
24 Adjuvants, Immunologic Phase 2
25 Gastrointestinal Agents Phase 2
26 Anti-Ulcer Agents Phase 2
27 Antacids Phase 2
28 Vaccines Phase 1, Phase 2
29 Rho(D) Immune Globulin Phase 2
30 gamma-Globulins Phase 2
31 Antibodies Phase 2
32 Immunoglobulins Phase 2
33 Immunologic Factors Phase 1, Phase 2
34 Immunoglobulins, Intravenous Phase 2
35 Interferon Inducers Phase 1, Phase 2
36 interferons Phase 1, Phase 2
37 poly(I).poly(c12,U) Phase 1, Phase 2
38 Poly I-C Phase 1, Phase 2
39
Imiquimod Approved, Investigational Phase 1 99011-02-6 57469
40
Peramivir Approved, Investigational Phase 1 229614-55-5, 330600-85-6 151164
41
Inulin Approved, Investigational, Nutraceutical Phase 1 9005-80-5 24763
42 ISCOMs Phase 1

Interventional clinical trials:

(show top 50) (show all 172)
# Name Status NCT ID Phase Drugs
1 Oseltamivir (Tamiflu) Dosing Strategies for Use During Influenza Prophylaxis (VA01) Completed NCT00304434 Phase 4 Oseltamivir;Probenecid
2 Human Immune Responses to an Adjuvanted H5 Vaccine: Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response Active, not recruiting NCT03701061 Phase 4
3 A Phase 3 Randomized, Observer-Blind, Multi-center, Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age Completed NCT02839330 Phase 3
4 A Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1when Administered to Adult and Elderly Subjects With and Without Immunosuppressive Conditions Completed NCT02107807 Phase 3
5 A Phase 2/3 Double Blinded, Randomized, Placebo-controlled Study in Healthy Adult Volunteers in Vietnam to Examine the Safety and Immunogenicity of an Inactivated A/H5N1 Influenza Vaccine (IVACFLU-A/H5N1) Produced by IVAC Completed NCT02612909 Phase 2, Phase 3
6 A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects Completed NCT00434733 Phase 3
7 Safety and Immunogenicity of Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age Completed NCT01310413 Phase 3
8 Safety and Tolerability of GSK 1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure Completed NCT01788228 Phase 3
9 A Blinded, Randomized Phase 2/3 Study to Assess Immunogenicity and Safety of Two Different Dose Levels of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Healthy Japanese Adult Population Aged 18 to 59 Years Completed NCT01382329 Phase 2, Phase 3
10 Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Immunogenicity and Safety of 'MG1109(Egg-based, Pre-pandemic Influenza(H5N1) Vaccine)' Administered Intramuscularly in Healthy Adult Volunteers Completed NCT01987011 Phase 3
11 Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 When Administered to Adult and Elderly Subjects With and Without Underlying Medical Conditions. Completed NCT02091908 Phase 3
12 Evaluation of the Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok® Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine In Healthy Adults Aged 18 to 49 Completed NCT00539981 Phase 3
13 Evaluation of the Immunogenicity and Safety of Two Preparations of Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine Administered Intramuscularly in Healthy Adults Ages 18-49 Years. Completed NCT00328107 Phase 2, Phase 3
14 Efficacy of Oseltamivir in Reducing the Duration of Clinical Illness, Viral Shedding, and Transmissibility Reduction Within Households Among Participants in an Influenza Disease Burden Surveillance Cohort in Urban Dhaka, Bangladesh Completed NCT00707941 Phase 3 Oseltamivir;Placebo
15 SEA022 Oseltamivir Treatment in Children Under One Year of Age With Moderate or Severe Influenza Lower Respiratory Tract Infection - a Clinical and Pharmacokinetic Study. Withdrawn NCT01546935 Phase 2, Phase 3 Oseltamivir
16 A Single Center, Open-label, Phase I/II Study of Two 90 Microgram Doses of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses Unknown status NCT00417560 Phase 1, Phase 2
17 A Phase II, Single Center, Exploratory Study to Evaluate Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With MF59-adjuvanted or Non-adjuvanted H5N3 Influenza Vaccines Completed NCT00478816 Phase 2
18 A Phase II, Randomized, Controlled, Observer-blind, Single-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of an H5N1 Influenza Vaccine in Subjects Aged 6 Months to 17 Years Completed NCT00537524 Phase 2
19 Evaluation of Priming Effects by Pandemic Live Attenuated Influenza Vaccine (LAIV Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2)) on the Subsequent Response to Inactivated H5N1 Vaccine in Healthy Thai Volunteers: A Non-Randomized, Open Label Study Completed NCT02229357 Phase 2
20 A Trial to Evaluate the Immunogenicity of Accelerated Primary Vaccination With Monovalent A/Indonesia/5/05 (H5N1) Vaccine Antigen in Association With AS03 Adjuvant in Adults Aged 18-64 Completed NCT00695669 Phase 2
21 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without AS03 Adjuvant (HIPC: VAX-010) Completed NCT01910519 Phase 2
22 High-Dose Versus Standard-Dose Oseltamivir for the Treatment of Severe Influenza and Avian Influenza: A Phase II Double-Blind, Randomized Clinical Trial Completed NCT00298233 Phase 2 Oseltamivir
23 A Phase II, Randomized, Controlled, Open Label, Single-Center Study to Evaluate the Immunogenicity, Safety and Tolerability of an H5N1-vaccine and a Seasonal Influenza Vaccine in Adult Subjects Completed NCT00481065 Phase 2
24 Characterization of Innate Immune Responses to AS03 Adjuvanted H5N1 Vaccine Compared to Non-adjuvanted H5N1 Vaccine Completed NCT01578317 Phase 1, Phase 2
25 A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects Completed NCT02436928 Phase 1, Phase 2
26 A Phase II Randomized Study of the Safety and Immunogenicity of Vaccination Strategies Using One or Two Clades and Different Schedules of H5N1 Unadjuvanted, Inactivated Subvirion Influenza Vaccines in H5 Naïve Healthy Adults Completed NCT00703053 Phase 2
27 A Phase II, Open-label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Booster Dose of -H5N1 (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccine in Non-elderly Adult and Elderly Subjects Completed NCT00561184 Phase 2
28 A Multicenter, Open-Label Study to Assess the Immunogenicity and Safety of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Healthy Young Adults Primed With a Two-Vaccination of a Recombinant H5N1 Influenza HA Vaccine Completed NCT01195038 Phase 2
29 A Phase I/II Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Anhui/1/13 (H7N9) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Adults With and Without Matrix-M1™ Completed NCT02078674 Phase 1, Phase 2
30 A Multicenter, Non-Blinded, Dose Escalation Study to Evaluate the Immunogenicity, Safety and Optimal Dose of Three Doses Regimen of Recombinant Influenza H5N1 Vaccine, After Two Vaccinations Given 3 Weeks Apart, in Healthy Young Adults. Completed NCT00980447 Phase 2
31 Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities Completed NCT00311649 Phase 1, Phase 2
32 A Randomized, Double-Blinded, Phase I/II Study of the Safety, Reactogenicity, and Immunogenicity of an Inactivated Influenza Vaccine Derived From A/H5N1/Indonesia/05/05 (Clade 2) in Healthy Adults and Elderly Who Participated in a Previous A/H5N1/Vietnam/1203/2004 (Clade 1) Vaccine Study Completed NCT00680069 Phase 1, Phase 2
33 A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant Completed NCT03312231 Phase 2 AS03
34 A Phase II Study to Evaluate and Compare the Immunogenicity of Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered With and Without AS03 Adjuvant and Monovalent Inactivated Influenza A/H3N2v Virus Vaccine Administered Without Adjuvant in Healthy Adults Through Standard and Systems Biology Analyses Completed NCT02921997 Phase 2 AS03
35 A Phase II Randomized, Partially-Blinded, Controlled Trial in Healthy Adults Aged 65 Years and Older to Assess the Safety, Reactogenicity, and Immunogenicity of an MF59-Adjuvanted, Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered Intramuscularly at Different Intervals and Dosages Completed NCT02213354 Phase 2 MF59
36 A Phase II Study in Healthy Adults (19-64 Years of Age) to Assess the Safety, Reactogenicity and Immunogenicity of Sequential or Simultaneous Intramuscular Administration of an AS03-adjuvanted A/H7N9 Inactivated Influenza Vaccine With Seasonal Influenza Vaccine Completed NCT03318315 Phase 2 AS03
37 Immunogenicity and Safety Study of GSK Biologicals' Monovalent Pandemic H5N1 Vaccine 1557484A in Adults Aged 18 - 64 Years Completed NCT01416571 Phase 2
38 A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects. Completed NCT01776554 Phase 2
39 A Phase II, Randomized, Observer-Blind,Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects. Completed NCT01776541 Phase 2
40 A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects. Completed NCT01766921 Phase 2
41 Phase II Study of a Pandemic Influenza Vaccine in Elderly Participants Completed NCT00376402 Phase 2
42 Phase II Study of a Pandemic Influenza Vaccine in Children Completed NCT00370864 Phase 2
43 A Phase II, Randomized, Controlled, Double-blind, Multi-center, Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines Containing 3.75 µg or 7.5 μg of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects Completed NCT00914771 Phase 2
44 A Phase 1/2 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 Months to 17 Years Completed NCT01052402 Phase 1, Phase 2
45 A Phase 1/2, Randomized, Open-Label, Study to Assess the Immunogenicity and Safety of a Vaccine Enhancement Patch (VEP) When Administered With Two Doses of Intramuscular Inactivated Influenza H5N1 Vaccine in Healthy Adults Completed NCT01353534 Phase 1, Phase 2 Vaccine Enhancement Patch
46 An Open-Label Phase 1/2 Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule With a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Volunteers Aged 18 to 59 Years Completed NCT00895544 Phase 1, Phase 2
47 Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in European Children Completed NCT00884182 Phase 2
48 A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age Completed NCT00771615 Phase 2
49 A Double-Blind, Randomised, Multi-Centre Study to Evaluate the Safety, Tolerability, Immunogenicity and Lot to Lot Consistency of Two Formulations of CSL Limited's Inactivated Prototype Pandemic Influenza Vaccine in a Healthy Adult Population (≤18 Years to ≥64 Years of Age). Completed NCT00320346 Phase 2
50 Randomized Phase I/II Study to Evaluate the Safety and Immunogenicity of 'MG1109(Egg-based, Pre-pandemic Influenza(H5N1) Vaccine)' Administered Intramuscularly in Healthy Adult Volunteers Completed NCT01389466 Phase 1, Phase 2

Search NIH Clinical Center for Avian Influenza

Cochrane evidence based reviews: influenza in birds

Genetic Tests for Avian Influenza

Anatomical Context for Avian Influenza

MalaCards organs/tissues related to Avian Influenza:

40
Testes, Lung, T Cells, Eye, B Cells, Brain, Endothelial

Publications for Avian Influenza

Articles related to Avian Influenza:

(show top 50) (show all 10090)
# Title Authors PMID Year
1
Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts. 61 42
31266524 2019
2
Successful management of refractory respiratory failure caused by avian influenza H7N9 and secondary organizing pneumonia: a case report and literature review. 42 61
31357937 2019
3
Glucocorticoid treatment of suspected organizing pneumonia after H7N9 infection: A case report. 42
31441857 2019
4
Identification of antigenic epitopes in the haemagglutinin protein of H7 avian influenza virus. 61
31508993 2020
5
Co-infections of chickens with avian influenza virus H9N2 and Moroccan Italy 02 infectious bronchitis virus: effect on pathogenesis and protection conferred by different vaccination programmes. 61
31412705 2020
6
Direct visualization of avian influenza H5N1 hemagglutinin precursor and its conformational change by high-speed atomic force microscopy. 61
30825615 2020
7
Why are vaccines against many human viral diseases still unavailable; an historic perspective? 61
31502669 2020
8
Host-Specific Restriction of Avian Influenza Virus Caused by Differential Dynamics of ANP32 Family Members. 61
31581291 2020
9
Recommended hospital preparations for future cases and outbreaks of novel influenza viruses. 61
31648548 2020
10
Organ-specific small non-coding RNA responses in domestic (Sudani) ducks experimentally infected with highly pathogenic avian influenza virus (H5N1). 61
31538530 2020
11
Limited changes in the fecal microbiome composition of laying hens after oral inoculation with wild duck feces. 61
31541252 2019
12
Continuing evolution of H6N2 influenza a virus in South African chickens and the implications for diagnosis and control. 61
31852473 2019
13
HA-Dependent Tropism of H5N1 and H7N9 Influenza Viruses to Human Endothelial Cells Is Determined by Reduced Stability of the HA, Which Allows the Virus To Cope with Inefficient Endosomal Acidification and Constitutively Expressed IFITM3. 61
31597765 2019
14
A novel recombinant avian leukosis virus isolated from gamecocks induced pathogenicity in Three-Yellow chickens: a potential infection source of avian leukosis virus to the commercial chickens. 61
31549168 2019
15
A novel Bursin-like peptide as a potential virus inhibitor and immunity regulator in SPF chickens infected with recombinant ALV. 61
31823780 2019
16
Mimicking the passage of avian influenza viruses through the gastrointestinal tract of chickens. 61
31767100 2019
17
Avian influenza viruses in humans: lessons from past outbreaks. 61
31848585 2019
18
Laboratory-Confirmed Avian Influenza A(H9N2) Virus Infection, India, 2019. 61
31742537 2019
19
Novel Avian Influenza A Virus Infections of Humans. 61
31668198 2019
20
Inferring host roles in bayesian phylodynamics of global avian influenza A virus H9N2. 61
31586866 2019
21
Inventory of molecular markers affecting biological characteristics of avian influenza A viruses. 61
31428925 2019
22
Genetic Characterization of Avian Influenza A(H5N6) Virus Clade 2.3.4.4, Russia, 2018. 61
31742535 2019
23
Role for migratory domestic poultry and/or wild birds in the global spread of avian influenza? 61
31752591 2019
24
The Assessment of Twitter's Potential for Outbreak Detection: Avian Influenza Case Study. 61
31796768 2019
25
Genetic Characteristics and Pathogenicity Analysis in Chickens and Mice of Three H9N2 Avian Influenza Viruses. 61
31817585 2019
26
Highly Pathogenic Avian Influenza A(H5N8) Virus in Gray Seals, Baltic Sea. 61
31742519 2019
27
Evolution of Highly Pathogenic Avian Influenza A(H5N1) Virus in Poultry, Togo, 2018. 61
31742528 2019
28
Avian Influenza A Viruses among Occupationally Exposed Populations, China, 2014-2016. 61
31742536 2019
29
Ultrasensitive SERS determination of avian influenza A H7N9 virus via exonuclease III-assisted cycling amplification. 61
31450475 2019
30
Correction to: Effect of closure of live poultry markets in China on prevention and control of human infection with H7N9 avian influenza: a case study of four cities in Jiangsu Province. 61
31827237 2019
31
Effect of closure of live poultry markets in China on prevention and control of human infection with H7N9 avian influenza: a case study of four cities in Jiangsu Province. 61
31527787 2019
32
Long-lasting protective immunity against H7N9 infection is induced by intramuscular or CpG-adjuvanted intranasal immunization with the split H7N9 vaccine. 61
31806571 2019
33
Incorporating heterogeneous sampling probabilities in continuous phylogeographic inference - application to H5N1 spread in the Mekong region. 61
31790143 2019
34
Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination. 61
31845904 2019
35
A Phase 2/3 double blinded, randomized, placebo-controlled study in healthy adult participants in Vietnam to examine the safety and immunogenicity of an inactivated whole virion, alum adjuvanted, A(H5N1) influenza vaccine (IVACFLU-A/H5N1). 61
31812464 2019
36
Statistical characteristics of amino acid covariance as possible descriptors of viral genomic complexity. 61
31804522 2019
37
Ifenprodil and Flavopiridol Identified by Genomewide RNA Interference Screening as Effective Drugs To Ameliorate Murine Acute Lung Injury after Influenza A H5N1 Virus Infection. 61
31822599 2019
38
Outbreaks of Clade 2.3.4.4 H5N8 highly pathogenic avian influenza in 2018 in the northern regions of South Africa were unrelated to those of 2017. 61
31833671 2019
39
Analysis of antibody response to an epitope in the haemagglutinin subunit 2 of avian influenza virus H5N1 for differentiation of infected and vaccinated chickens. 61
31738584 2019
40
Transcriptional and Pathological Host Responses to Coinfection with Virulent or Attenuated Mycoplasma gallisepticum and Low-Pathogenic Avian Influenza A Virus in Chickens. 61
31591166 2019
41
Novel protein microarray for the detection of avian influenza virus antibodies and simultaneous distinction of antibodies against H5 and H7 subtypes. 61
31232095 2019
42
Characterization and Phylodynamics of Reassortant H12Nx Viruses in Northern Eurasia. 61
31816947 2019
43
Smartphone-Based Point-of-Care Microfluidic Platform Fabricated with a ZnO Nanorod Template for Colorimetric Virus Detection. 61
31769284 2019
44
Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice. 61
31757769 2019
45
Rapid detection of avian leukosis virus using a fluorescent microsphere immunochromatographic test strip assay. 61
31553793 2019
46
One health approach in Nepal: Scope, opportunities and challenges. 61
31485475 2019
47
The RISKSUR EVA tool (Survtool): A tool for the integrated evaluation of animal health surveillance systems. 61
31731037 2019
48
A qualitative risk assessment of cleansing and disinfection requirements after an avian influenza outbreak in commercial poultry. 61
31474117 2019
49
Avian influenza virus transmission is suppressed in chickens fed Lactobacillus paracasei expressing the 3D8 single-chain variable fragment protein. 61
31842597 2019
50
Molecular evolution and amino acid characteristics of newly isolated H9N2 avian influenza viruses from Liaoning Province, China. 61
31801929 2019

Variations for Avian Influenza

Expression for Avian Influenza

Search GEO for disease gene expression data for Avian Influenza.

Pathways for Avian Influenza

Pathways related to Avian Influenza according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 TNF STAT2 NEU1 JUN ISG15 IRF7
2
Show member pathways
13.33 TNF JUN IL6 CXCL8 CXCL10 CRK
3
Show member pathways
13.04 TNF STAT2 ISG15 IRF7 IL6 IFNA1
4
Show member pathways
13.02 TNF STAT2 ISG15 IL6 IFNA1 HSP90AA1
5
Show member pathways
12.98 TNF JUN IL6 HSP90AA1 CRK CCR5
6
Show member pathways
12.96 TNF STAT2 SFTPD JUN IRF7 IL6
7
Show member pathways
12.87 TNF IL6 IFNA1 HSP90AA1 CXCL8
8
Show member pathways
12.87 STAT2 JUN HSP90AA1 CXCL8 CXCL10 CRK
9
Show member pathways
12.85 TNF STAT2 JUN IRF7 IL6 IFNA1
10 12.82 TNF STAT2 IRF7 IL6 IFNA1 DDX58
11 12.82 STAT2 JUN IL6 IFNA1 HSP90AA1 CXCL8
12
Show member pathways
12.7 TNF ISG15 IRF7 IL6 IFNA1 DDX58
13
Show member pathways
12.62 TNF JUN IL6 CRK CCR5
14
Show member pathways
12.57 STAT2 ISG15 IRF7 IFNA1 DDX58
15 12.55 TNF STAT2 IRF7 IFNA1 DDX58 CXCL10
16 12.4 TNF JUN CXCL8 CRK
17
Show member pathways
12.36 TNF STAT2 JUN ISG15 IRF7 IL6
18
Show member pathways
12.35 TNF IL6 CXCL8 CXCL10 CCR5
19
Show member pathways
12.34 TNF JUN IL6 CXCL8 CRK
20 12.32 TNF JUN IL6 CXCL8
21
Show member pathways
12.31 TNF JUN IL6 HSP90AA1 CXCL8 CXCL10
22
Show member pathways
12.27 TNF JUN IRF7 IL6 CXCL8
23
Show member pathways
12.25 TNF JUN IL6 CXCL8
24
Show member pathways
12.24 TNF STAT2 IFNA1 HSP90AA1
25
Show member pathways
12.24 TNF STAT2 JUN IL6
26 12.2 TNF JUN IL6 CXCL8
27
Show member pathways
12.15 TNF SFTPD JUN IL6 CXCL8 CXCL10
28
Show member pathways
12.08 TNF STAT2 JUN IL6
29
Show member pathways
12.07 TNF STAT2 ISG15 IRF7 IL6 IFNA1
30 12.04 TNF IL6 CXCL8 CXCL10
31 12.02 TNF IL6 HSP90AA1 CXCL8
32 12 TNF JUN IL6 CXCL10
33 11.99 TNF JUN IL6 CXCL8 CRK
34 11.97 JUN IRF7 IL6 CXCL8
35 11.94 TNF JUN IL6 CXCL8
36 11.92 STAT2 IL6 IFNA1 CCR5
37 11.89 TNF JUN IL6 CXCL8
38 11.83 JUN IL6 HSP90AA1 CXCL8
39 11.81 JUN IL6 CXCL8
40
Show member pathways
11.78 TNF JUN CXCL8
41 11.78 TNF JUN IL6 CXCL8
42 11.75 TNF IL6 CXCL10
43 11.7 JUN IL6 CXCL8 CRK
44 11.69 TNF IL6 CXCL8
45
Show member pathways
11.68 TNF JUN IL6 CXCL8
46 11.64 TNF IL6 CXCL8
47 11.63 JUN IL6 CXCL8
48 11.58 JUN IL6 CXCL8
49 11.57 TNF IL6 CXCL8
50 11.55 TNF JUN HSP90AA1

GO Terms for Avian Influenza

Cellular components related to Avian Influenza according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 TNF SFTPD PCSK6 PCSK5 IL6 IFNA1
2 extracellular region GO:0005576 9.4 TNF SFTPD PCSK6 PCSK5 NEU1 ISG15

Biological processes related to Avian Influenza according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.14 TNF STAT2 JUN IRF7 IL6 DDX58
2 immune response GO:0006955 10.02 TNF IL6 CXCL8 CXCL10 CCR5
3 viral process GO:0016032 9.99 STAT2 IVNS1ABP ISG15 IRF7 DDX58 CCR5
4 inflammatory response GO:0006954 9.95 TNF IL6 CXCL8 CXCL10 CCR5
5 cellular response to lipopolysaccharide GO:0071222 9.83 TNF IL6 CXCL8 CXCL10 CCR5
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.81 TNF IL6 HSP90AA1
7 chemokine-mediated signaling pathway GO:0070098 9.78 CXCL8 CXCL10 CCR5
8 positive regulation of interleukin-6 production GO:0032755 9.76 TNF IL6 DDX58
9 positive regulation of smooth muscle cell proliferation GO:0048661 9.75 TNF JUN IL6
10 protein processing GO:0016485 9.74 PCSK6 PCSK5 FURIN
11 humoral immune response GO:0006959 9.73 TNF IL6 IFNA1
12 response to virus GO:0009615 9.72 TNF IVNS1ABP IRF7 DDX58 CXCL10
13 type I interferon signaling pathway GO:0060337 9.71 STAT2 ISG15 IRF7 IFNA1
14 peptide hormone processing GO:0016486 9.65 PCSK6 PCSK5 FURIN
15 positive regulation of neuroinflammatory response GO:0150078 9.63 TNF IL6
16 positive regulation of interferon-alpha production GO:0032727 9.63 IRF7 DDX58
17 embryonic digestive tract development GO:0048566 9.63 TNF PCSK5 CXCL8
18 defense response GO:0006952 9.63 TNF STAT2 IFNA1 CXCL8 CXCL10 CCR5
19 signal peptide processing GO:0006465 9.62 PCSK5 FURIN
20 secretion by cell GO:0032940 9.61 PCSK6 FURIN
21 negative regulation of lipid storage GO:0010888 9.6 TNF IL6
22 negative regulation of macrophage apoptotic process GO:2000110 9.54 IRF7 CCR5
23 regulation of lipoprotein lipase activity GO:0051004 9.54 PCSK6 PCSK5 FURIN
24 peptide biosynthetic process GO:0043043 9.52 PCSK5 FURIN
25 defense response to virus GO:0051607 9.5 STAT2 ISG15 IRF7 IL6 IFNA1 DDX58
26 nerve growth factor production GO:0032902 9.49 PCSK6 FURIN
27 nerve growth factor processing GO:0032455 9.43 PCSK6 PCSK5 FURIN
28 cytokine-mediated signaling pathway GO:0019221 9.28 TNF STAT2 IL6 IFNA1 HSP90AA1 CXCL8

Molecular functions related to Avian Influenza according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 TNF TMPRSS13 STAT2 SFTPD PCSK6 PCSK5
2 serine-type endopeptidase activity GO:0004252 9.62 TMPRSS13 PCSK6 PCSK5 FURIN
3 endopeptidase activity GO:0004175 9.54 PCSK6 PCSK5 FURIN
4 serine-type peptidase activity GO:0008236 9.46 TMPRSS13 PCSK6 PCSK5 FURIN
5 nerve growth factor binding GO:0048406 9.26 PCSK6 FURIN
6 cytokine activity GO:0005125 9.02 TNF IL6 IFNA1 CXCL8 CXCL10

Sources for Avian Influenza

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....